Biohaven Investor and Clinician Dinner in Philadelphia

May 7, 2019

Please join Biohaven for an informative Investor and Clinician dinner as leading experts discuss the advancement of the Biohaven NOJECTION™ CGRP antagnonist platform.

Guest Speakers:
Richard Lipton, MD
Albert Einstein College of Medicine Montefiore Headache Center

David Kudrow, MD
California Medical Clinic for Headache

Jelena Pavlovic, MD
Albert Einstein College of Medicine Montefiore Headache Center


Date:
Tuesday, May 7th, 2019
 
Time:
Registration: 6:30pm
Presentation & Dinner: 7:00pm
 

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Biohaven Pharmaceuticals, Inc [BHVN] US$2,487 MM MCap
Pre­sent­ed ex­pand­ed da­ta at AHS (Ju­ly 2019) /dosed 1,780+ pa­tients (com­bined ex­po­sure of 105k dos­es) and ex­pand­ed safe­ty & pre­lim pre­ven­tive ef­fi­ca­cy da­ta (May 2019) from long-term safe­ty study. Up­com­ing mile­s­tones: Ph 3 to­p­line da­ta in pre­ven­tive treat­ment of mi­graine (rimege­pant) & Ph 2/3 to­p­line ef­fi­ca­cy & safe­ty in in­tra­nasal (BHV-3500) for acute treat­ment of mi­graine in 4Q19. [more in­for­ma­tion]